Jonas Schoendube
Direktor/Vorstandsmitglied bei Cytena Bioprocess Solutions
Profil
Jonas Schoendube was the founder and former Chief Executive Officer of Cytena GmbH, which was founded in 2014.
He is currently a Director at Cytena Bioprocess Solutions.
He previously worked as a Manager-Business Area Biosciences at BICO Group AB.
Dr. Schoendube holds a doctorate from the University of Freiburg and a graduate degree from the Swiss Federal Institute of Technology.
Aktive Positionen von Jonas Schoendube
| Unternehmen | Position | Beginn |
|---|---|---|
| Cytena Bioprocess Solutions | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Jonas Schoendube
| Unternehmen | Position | Ende |
|---|---|---|
cytena GmbH
 cytena GmbH BiotechnologyHealth Technology cytena GmbH develops a device for separating of single cells. It has developed a device called cy-Clone to separate single cells and these single cells are required for the development of state-of-the-art drugs, so-called biologicals as well as for the genetic analysis of single cells for cancer and stem cell research, the cy-Clone is supported by an automated imaging process to encapsulate cells in droplets, which are delivered to any type of substrate. The company was founded by Peter Koltay, Benjamin Steimle, Jonas Schoendube and Andre Gross in August 2014 and is headquartered in Freiburg, Germany. | Vorstandsvorsitzender | 01.05.2021 |
| BICO GROUP AB | Corporate Officer/Principal | - |
Ausbildung von Jonas Schoendube
| Swiss Federal Institute of Technology | Graduate Degree |
| University of Freiburg | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BICO GROUP AB | Health Technology |
| Private Unternehmen | 2 |
|---|---|
cytena GmbH
cytena GmbH BiotechnologyHealth Technology cytena GmbH develops a device for separating of single cells. It has developed a device called cy-Clone to separate single cells and these single cells are required for the development of state-of-the-art drugs, so-called biologicals as well as for the genetic analysis of single cells for cancer and stem cell research, the cy-Clone is supported by an automated imaging process to encapsulate cells in droplets, which are delivered to any type of substrate. The company was founded by Peter Koltay, Benjamin Steimle, Jonas Schoendube and Andre Gross in August 2014 and is headquartered in Freiburg, Germany. | Health Technology |
| Cytena Bioprocess Solutions |
